Entest Biomedical Inc
Entest Group, Inc. does not have significant operations. It intends to seek business opportunities to review and analyze for purposes of effecting a merger, acquisition, or other business combination with an operating company business. The company was formerly known as Entest Biomedical, Inc. and changed its name to Entest Group, Inc. in February 2018. Entest Group, Inc. was founded in 2008 and i… Read more
Entest Biomedical Inc (ETNI) - Net Assets
Latest net assets as of November 2019: $-50.66K USD
Based on the latest financial reports, Entest Biomedical Inc (ETNI) has net assets worth $-50.66K USD as of November 2019.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($0.00) and total liabilities ($50.66K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-50.66K |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 623.23 |
Entest Biomedical Inc - Net Assets Trend (2009–2019)
This chart illustrates how Entest Biomedical Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Entest Biomedical Inc (2009–2019)
The table below shows the annual net assets of Entest Biomedical Inc from 2009 to 2019.
| Year | Net Assets | Change |
|---|---|---|
| 2019-08-31 | $-32.67K | +86.70% |
| 2018-08-31 | $-245.71K | -1560.48% |
| 2017-08-31 | $16.82K | +101.72% |
| 2016-08-31 | $-978.87K | -24.32% |
| 2015-08-31 | $-787.38K | -15.93% |
| 2014-08-31 | $-679.18K | +1.12% |
| 2013-08-31 | $-686.88K | -1088.39% |
| 2012-08-31 | $-57.80K | -133.66% |
| 2011-08-31 | $171.74K | +177.80% |
| 2010-08-31 | $-220.74K | -376.98% |
| 2009-08-31 | $79.69K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Entest Biomedical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 981858500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (August 2019)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.92K | % |
| Other Components | $10.03 Million | % |
| Total Equity | $-32.67K | 100.00% |
Entest Biomedical Inc Competitors by Market Cap
The table below lists competitors of Entest Biomedical Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rocca SA
WAR:RCA
|
$9.84K |
|
Bioventix
LSE:BVXP
|
$9.85K |
|
Wells Fargo & Company PFD DIV EQUALIZ
PINK:WFCNP
|
$9.86K |
|
Valeo Pharma Inc
PINK:VPHIF
|
$9.87K |
|
ENGEN BOTSTWANA LIMITED
XBOT:ENG-EQO
|
$9.82K |
|
JIANGSU EXPRESS -H- (JE2.SG)
STU:JE2
|
$9.81K |
|
OCCL Limited
NSE:OCCLLTD
|
$9.81K |
|
ISFELAG HF
IC:ISF
|
$9.81K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Entest Biomedical Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2018 to 2019, total equity changed from -245,711 to -32,671, a change of 213,040.
- Net income of 191,618 contributed positively to equity growth.
- New share issuances of 1,821 increased equity.
- Other factors increased equity by 19,601.
Equity Change Factors (2018 to 2019)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $191.62K | +586.51% |
| Share Issuances | $1.82K | +5.57% |
| Other Changes | $19.60K | +60.0% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Entest Biomedical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-08-31 | $5.32 | $0.00 | x |
| 2010-08-31 | $-1.89 | $0.00 | x |
| 2011-08-31 | $1.29 | $0.00 | x |
| 2012-08-31 | $-0.09 | $0.00 | x |
| 2013-08-31 | $-0.22 | $0.00 | x |
| 2014-08-31 | $-0.07 | $0.00 | x |
| 2015-08-31 | $-0.05 | $0.00 | x |
| 2016-08-31 | $-0.02 | $0.00 | x |
| 2017-08-31 | $0.00 | $0.00 | x |
| 2018-08-31 | $-0.01 | $0.00 | x |
| 2019-08-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Entest Biomedical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-78.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -308.07% | 0.00% | 0.00x | 1.03x | $-253.48K |
| 2010 | 0.00% | -83.87% | 7.62x | 0.00x | $-522.82K |
| 2011 | -554.21% | -272.61% | 0.63x | 3.24x | $-968.96K |
| 2012 | 0.00% | -443.40% | 0.81x | 0.00x | $-1.88 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.26 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.35 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-406.54K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-409.11K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-555.05K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.45 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $194.89K |
Industry Comparison
This section compares Entest Biomedical Inc's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Entest Biomedical Inc (ETNI) | $-50.66K | -308.07% | N/A | $9.83K |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |